Back to Search
Start Over
Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
- Source :
- The Lancet; June 2024, Vol. 403 Issue: 10445 p2709-2719, 11p
- Publication Year :
- 2024
-
Abstract
- Tenosynovial giant cell tumour (TGCT) is a locally aggressive neoplasm for which few systemic treatment options exist. This study evaluated the efficacy and safety of vimseltinib, an oral, switch-control, CSF1R inhibitor, in patients with symptomatic TGCT not amenable to surgery.
Details
- Language :
- English
- ISSN :
- 01406736 and 1474547X
- Volume :
- 403
- Issue :
- 10445
- Database :
- Supplemental Index
- Journal :
- The Lancet
- Publication Type :
- Periodical
- Accession number :
- ejs66687437
- Full Text :
- https://doi.org/10.1016/S0140-6736(24)00885-7